Benefits of insulin degludec/liraglutide are maintained even in patients discontinuing sulphonylureas or dipeptidyl peptidase‐4 inhibitors upon initiation of degludec/liraglutide t...

por Janez, Andrej, Őrsy, Petra, Stachlewska, Karolina, Salvesen‐Sykes, Karen, Billings, Liana K., Philis‐Tsimikas, Athena
Publicado 2020

A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a...

por Sesti, Giorgio, Bardtrum, Lars, Dagdelen, Selcuk, Halladin, Natalie, Haluzík, Martin, Őrsy, Petra, Rodríguez, Martin, Aroda, Vanita R.
Publicado 2020

IDegLira improves patient‐reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal–bolus therapy

por Miller, Eden, Doshi, Ankur, Grøn, Randi, Jódar, Esteban, Őrsy, Petra, Ranthe, Mattis F., Sugimoto, Danny, Tentolouris, Nikolaos, Viljoen, Adie, Billings, Liana K.
Publicado 2019

Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10)

por Brown‐Frandsen, Kirstine, Emerson, Scott S., McGuire, Darren K., Pieber, Thomas R., Poulter, Neil R., Pratley, Richard E., Zinman, Bernard, Ranthe, Mattis F., Grøn, Randi, Lange, Martin, Moses, Alan C., Örsy, Petra, Buse, John B.
Publicado 2019